Výsledky vyhledávání - Idbaih, A
- Zobrazuji výsledky 1 - 20 z 28
- Přejít na další stránku
-
1
-
2
P04.10 Chains of magnetosomes induce full destruction of intracranial U87-Luc and subcutaneous GL-261 glioma in mice under the application of an alternating magnetic field Autor Alphandery, E, Idbaih, A, Adam, C, Delattre, J, Schmitt, C, Guyot, F, Chebbi, I
Vydáno 2018Text -
3
-
4
-
5
-
6
-
7
P05.05 Safety and feasibility of temporary blood-brain barrier disruption with the SonoCloud-1/3 implantable ultrasound device in recurrent glioblastoma Autor Idbaih, A, Canney, M, Bouchoux, G, Desseaux, C, Vignot, A, Lafon, C, Chapelon, J, Delattre, J, Belin, L, Carpentier, A
Vydáno 2019Text -
8
OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas Autor Rosenberg, S., Dehais, C., Ducray, F., Alentron, A., Tanguy, M., De Reyneis, A., Elarouci, N., Figarella-Branger, D., Delattre, J., Idbaih, A.
Vydáno 2017Text -
9
EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma Autor van den Bent, M., Gorlia, T., Bendszus, M., Sahm, F., Domont, J., Idbaih, A., Platten, M., Weller, M., Golfoinopoulos, V., Wick, W.
Vydáno 2016Text -
10
-
11
-
12
P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study Autor Alentorn, A., Carpentier, C., Labreche, K., Ducray, F., Dehais, C., Mokhtari, K., Uro-Coste, E., Figarella-Branger, D., Delattre, J., Idbaih, A.
Vydáno 2016Text -
13
O10.02 MITOTIC INDEX, MICROVASCULAR PROLIFERATION AND NECROSIS DEFINE THREE GROUPS OF 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS ASSOCIATED WITH DIFFERENT GENOMIC ALTERATIONS Autor Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Ducray, F., Idbaih, A., Network, French POLA
Vydáno 2014Text -
14
-
15
P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref... Autor Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.
Vydáno 2016Text -
16
P11.59 Integrin a5 heterogeneous expression in glioblastoma is related to glioma stem cell subpopulations Autor Dontenwill, M, Mercier, M, Gillmann, G, Reita, D, Lelong-Rebel, I, Noulet, F, Idbaih, A, Herold-Mende, C, Bagnard, D, Spenlé, C, Martin, S
Vydáno 2019Text -
17
OS8.5 How to assess meningioma therapy activity: The CEVOREM independent central review experience Autor GRAILLON, T, Colin, T, Peyrière, H, Peyre, M, Tabouret, E, Campello, C, Idbaih, A, Boucekine, M, Figarella-Branger, D, Kalamarides, M, Dufour, H, Sanson, M, Chinot, O
Vydáno 2019Text -
18
P17.01 CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY Autor Alentorn, A., Dehais, C., Carpentier, C., Mokhtari, K., Ducray, F., Figarella-Branger, D., Delattre, J., Idbaih, A., (POLA)”, POLA Network “Prise en charge des OLigodendrogliomes Anaplasiques
Vydáno 2014Text -
19
OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III E... Autor Taphoorn, M. J. B., Bottomley, A., Coens, C., Reijneveld, J. C., Gorlia, T., Brandes, A. A., Domont, J., Idbaih, A., van den Bent, M. J., Wick, W.
Vydáno 2016Text -
20
OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma Autor Idbaih, A., Clement, P. M., Vos, F. Y. F., Platten, M., Mulholland, P., Taphoorn, M. J. B., Lewis, L., Golfinopoulos, V., Gorlia, T., van den Bent, M. J.
Vydáno 2016Text